The studies by Evans et al. (2009) and Budzik et al. (2010) both focused on 3‐aryl‐4‐isoxazolecarboxamides as potent GPBAR1 (TGR5) agonists, aiming to modulate bile acid receptor activity to treat metabolic disorders like type 2 diabetes. This evidence concerns the gene GPBAR1 and metabolic disease.